Abstract:
Metronomic chemotherapy (MCT) is the rhythmic administration of low-dose cytotoxic
drugs over an extended length of time with little to no drug-free intervals. MCT has an
impact on the tumor milieu and tumor cells. The low-dose timetable, in specific, hinders
endothelial cells' ability to repair themselves, which has an anti-angiogenesis impact. MCT
causes immunological stimulation, which prompts the immune system to attack tumor
cells. Anti-angiogenic medications also improve the effectiveness of MCT when used in
conjunction with targeted treatment. The current analysis provides a summary of phase I,
phase II, and phase III clinical trials examining the effectiveness, side effects, and method
of action of MCT in patients with non-small cell lung cancer. (NSCLC). The potential of
MCT in treating NSCLC has also been considered. According to the current study, MCT
is an effective treatment for specific NSCLC patients with manageable systemic side
effects and financial viability for public health.
